NLRC4 and tuberculosis: It is strongly increased in sepsis, tuberculosis, and after Ebola vaccination as well as in autoinflammatory diseases such as rheumatoid arthritis, NLRC4-MAS, and NOMID, and shows slight overlap with the severe COVID-19 patients in group G1.